Addressing Urgent Unmet Medical Needs

Gram-negative Infections

Gram-negative Infections

Unmet Need of AMR

1.27M deaths globally in 2019

>$4.6B US healthcare costs in 2017

Opportunities

Substantial non-dilutive funding available to fund existing R&D

Strong partnership potential

  • Antibiotic deal flow increasing
  • ~$1.4 billion in recent acquisitions and licenses

Competitive Landscape

Significant decline in R&D

Few recent innovations in the space

80% of recent approvals are derivatives of known classes

NTM Lung Disease

NTM Lung Disease

Unmet Need

M. avium complex (MAC)

  • 50k U.S. patients
  • Limited treatment options with only one approved drug (Arikayce), improvements in safety/tolerability and oral dosing needed

M. abscessus (MAB)

  • 15k U.S. patients
  • No approved drugs; emerging clinical data for omadacycline

Competitive Landscape

New oral therapies needed

Recent clinical development setbacks leave no oral agents in development for MAC